Phase 2 N=56 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
Diabetes type1
Primary: Incidence of Treatment-emergent Adverse Events (TEAE) — 1; 6; 1; 19 Events
Phase 1 N=117 Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
HIV Infections
Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regime — 1; 0; 2; 5 Participants
Phase 2 N=34 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Malignant Pleural Mesothelioma · Mesothelioma
Primary: Disease Control Rate (DCR) — 75 percentage of participants
N/A N=15 Does an Occupational Therapy Program Enhance Mental Health Outcomes for Veterans Who Scuba Dive
Post Traumatic Stress Disorder · Depression · Anxiety
Primary: Satisfaction With Occupational Performance — 4.2; 4.1 score on a scale
Phase 2 N=29 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
Breast Cancer · Triple Negative Breast Cancer
Primary: Number and Percentage of Participants With Pathologic Complete Response (pCR) Rate — 8 Participants
Phase 4 N=160 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants
Phase 3 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Acinetobacter Baumannii-calcoaceticus Complex · Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia
Primary: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population — 12; 20 Participants
N/A N=12 MRI for Non-invasive Evaluation of Brain Stress
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
Phase 1 N=72 Behavior Change Techniques (BCTs) to Improve Low Intensity Physical Activity in Older Adults
Sedentary Behavior
Primary: Within-person Change in Daily Steps. — 120.85; 257.42 Daily Steps
Phase 2 N=25 Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Phase 1 N=21 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Brain Stem Neoplasm · Pineal Region Neoplasm · Recurrent Lymphoma
Primary: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat — 4 mg/m²
Phase 2 N=32 Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
Sleep Apnea, Obstructive
Primary: Duration of Obstructive Events — 22.72; 24.66 seconds
Phase 2 N=1,225 Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
SARS-CoV 2
Primary: Cumulative Number of Hospitalizations or Deaths Prior to Hospitalization — 17; 37 Participants — p=0.005